Preparing for Change: What 2026 Means for Physician Reimbursement and Care Delivery
As we approach 2026, the landscape of physician reimbursement and care delivery will not be business as usual. Between new legislation, major updates to the Medicare Physician Fee Schedule (PFS), and rapid advances in artificial intelligence (AI) and care technology, healthcare delivery is entering a period of significant transition.
Oncology Financial Advocacy Services Guidelines: Results of a Delphi Study by the ACCC’s Financial Advocacy Network
This research was presented, in part, as a poster at the 2022 ASCO Quality Care Symposium and online-only as an abstract at the 2023 ASCO Annual Meeting.
FDA Approves Epcoritamab-bysp for Follicular Lymphoma Indications
On November 18, 2025, the FDA approved epcoritamab-bysp (Epkinly) in combination with lenalidomide and rituximab (R2) for relapsed or refractory follicular lymphoma (FL).
